{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Garcia-Moreno H"],"funding":["Fundação para a Ciência e a Tecnologia (FCT)","German Research Foundation","CureSCA3","Hertie Academy for Clinical Neuroscience","Alzheimer Forschung Initiative e.V.","Mayo Clinic Neuroscience Focused Research Team","Department of Health's National Institute for Health Research Biomedical Research Centre's funding scheme","Mayo Clinic Center for Regenerative Medicine","Swedish Research Council","Amyotrophic Lateral Sclerosis Association","Alzheimer Drug Discovery Foundation (ADDF)","Deutsche Forschungsgemeinschaft","Albertson Parkinson's Research Foundation","European Research Council","ALF, Sweden","Sol Goldman Charitable Trust","The Netherlands Organisation for Health Research and Development","Federal Ministry of Education and Research","National Institute for Health Research University College London Hospitals Biomedical Research Centre UCLH","Regional Fund for Science and Technology (FRCT), PRO-SCIENTIA program, Azores Government","The Haworth Family Professorship in Neurodegenerative Diseases fund","Fundo Social Europeu (FSE)","SCA-network, Sweden","Department of Defense","German Federal Ministry of Education and Research","Robert Packard Center for ALS Research at Johns Hopkins","National Ataxia Foundation","Mayo Clinic Foundation","Medical Research Council","Target ALS Foundation","U.S. Department of Defense","European Union's Horizon 2020 research and innovation programme","Region Skåne, Sweden","Donald G and Jodi P Heeringa Family","Swedish State Support for Clinical Research","NIH/National Institute of Neurological Disorder and Stroke"],"pagination":["2439-2452"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9543545"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(8)"],"pubmed_abstract":["<h4>Background and purpose</h4>Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures.<h4>Methods</h4>To evaluate total tau (t-tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCHL1) and neurofilament light-chain (NfL) as fluid biomarkers in SCA3, ATXN3 mutation carriers (n = 143) and controls (n = 172) were clinically assessed, and the plasma concentrations of the four proteins were analysed on the Simoa HD-1 platform. Eleven ATXN3 mutation carrier cerebrospinal fluid samples were analysed for t-tau and phosphorylated tau (p-tau<sup>181</sup> ). A transgenic SCA3 mouse model (MJDTg) was used to measure cerebellar t-tau levels.<h4>Results</h4>Plasma t-tau levels were higher in mutation carriers below"],"journal":["European journal of neurology"],"pubmed_title":["Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3."],"pmcid":["PMC9543545"],"funding_grant_id":["01DN18022","NL‐18002CB","2018-02532","ZUK32/1","R01NS088689","2018‐02532","01ED1602A/B","R21NS084528","P01NS084974","R35NS097273","MR/N028767/1","01GQ1402","IRTG 2150","AFI13812","ALSRP AL130125","ALFGBG-720931","681712","NL-18002CB","201809-2016862","643417"],"pubmed_authors":["Solanky N","Infante J","Vasconcelos-Ferreira A","Prudencio M","Heslegrave A","Zetterberg H","Giunti P","Wszolek ZK","Garcia-Moreno H","Synofzik M","Raposo M","Petrucelli L","Klockgether T","Ferreira AF","Puschmann A","Thomas-Black G","Hanna Al-Shaikh R","Gorcenco S","Faber J","Santana MM","Lima M","Januario C","Hubener-Schmid J","Jansen-West KR","Schols L","Pereira de Almeida L","Reetz K"],"additional_accession":[]},"is_claimable":false,"name":"Tau and neurofilament light-chain as fluid biomarkers in spinocerebellar ataxia type 3.","description":"<h4>Background and purpose</h4>Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require biomarkers for use as outcome measures.<h4>Methods</h4>To evaluate total tau (t-tau), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCHL1) and neurofilament light-chain (NfL) as fluid biomarkers in SCA3, ATXN3 mutation carriers (n = 143) and controls (n = 172) were clinically assessed, and the plasma concentrations of the four proteins were analysed on the Simoa HD-1 platform. Eleven ATXN3 mutation carrier cerebrospinal fluid samples were analysed for t-tau and phosphorylated tau (p-tau<sup>181</sup> ). A transgenic SCA3 mouse model (MJDTg) was used to measure cerebellar t-tau levels.<h4>Results</h4>Plasma t-tau levels were higher in mutation carriers below","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T12:07:51.058Z","creation":"2025-04-06T00:12:20.751Z"},"accession":"S-EPMC9543545","cross_references":{"pubmed":["35478426"],"doi":["10.1111/ene.15373"]}}